EIT Pharma Appoints Dr. Joseph Toerner, M.D., M.P.H., as Chief Medical Officer
EIT Pharma, Inc. today announced the appointment of Dr. Joseph Toerner, M.D., M.P.H., as Chief Medical Officer, effective immediately. Dr. Toerner brings 26 years of experience at the U.S. Food and Drug Administration (FDA), including leadership roles in hepatology, infectious diseases, and drug safety.
EIT Pharma Presents New Lonafarnib Analyses at the 2026 Delta Cure International Meeting
EIT Pharma, Inc. today highlighted three presentations at the 5th Edition of the Delta Cure International Meeting in Milan, Italy. The Company presented new analyses from its lonafarnib development program for Chronic Hepatitis Delta (CHD), covering the durability of response after treatment ends, histologic improvement and the clinical significance of alanine aminotransferase (ALT) dynamics following treatment cessation.
EIT Pharma to Sponsor and Present at the 2026 Delta Cure International Meeting
EIT Pharma, Inc. today announced it will sponsor and present at the 5th Edition of the Delta Cure International Meeting to be held on October 15-16, 2026, in Milan, Italy. Delta Cure is recognized as the leading international forum dedicated to Hepatitis Delta Virus.
EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners
EIT Pharma, Inc. today announced the successful close of an oversubscribed $35 million Series A financing round. The round was led by Propel Bio Partners, with participation from Good Ventures, Arrowtown, and others.
EIT Pharma Announces FDA Acceptance of New Drug Application for Lonafarnib for Treatment of Chronic Hepatitis D
EIT Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lonafarnib for the treatment of chronic hepatitis D.
EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026
EIT Pharma presented new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026. Due to the high unmet medical need in CHD, EIT Pharma resurrected the development of lonafarnib as the only late-stage oral option in late-stage development.